Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100–Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective—: The effects of extended-release niacin (ERN; 1–2 g/d) on the metabolism of lipoprotein(a) (Lp(a)) and apolipoprotein (apo) B-100–containing lipoproteins were investigated in 11 statin-treated white men with type 2 diabetes mellitus in a randomized, crossover trial of 12-weeks duration. Approach and Results—: The kinetics of Lp(a) and very low–density lipoprotein (VLDL), intermediate-density lipoprotein, and low-density lipoprotein (LDL) apoB-100 were determined following a standardized oral fat load (87% fat) using intravenous administration of D 3 -leucine, gas chromatography–mass spectrometry, and compartmental modeling. ERN significantly decreased fasting plasma total cholesterol, LDL cholesterol, and triglyceride concentrations. These effects were achieved without significant changes in body weight or insulin resistance. ERN significantly decreased plasma Lp(a) concentration (−26.5%) and the production rates of apo(a) (−41.5%) and Lp(a)-apoB-100 (−32.1%); the effect was greater in individuals with elevated Lp(a) concentration. ERN significantly decreased VLDL (−58.7%), intermediate-density lipoprotein (−33.6%), and LDL (−18.3%) apoB-100 concentrations and the corresponding production rates (VLDL, −49.8%; intermediate-density lipoprotein, −44.7%; LDL, −46.1%). The number of VLDL apoB-100 particles secreted increased in response to the oral fat load. Despite this, total VLDL apoB-100 production over the 10-hour postprandial period was significantly decreased with ERN (−21.9%). Conclusions—: In statin-treated men with type 2 diabetes mellitus, ERN decreased plasma Lp(a) concentrations by decreasing the production of apo(a) and Lp(a)-apoB-100. ERN also decreased the concentrations of apoB-100–containing lipoproteins by decreasing VLDL production and the transport of these particles down the VLDL to LDL cascade. Our study provides further mechanistic insights into the lipid-regulating effects of ERN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“including the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treament of HDL to Reduce the Incidence of Vascular Events (HPS-2 THRIVE), where niacin is added to aggressive LDL cholesterol–lowering statin thera…”
MethodBarr, E. L. M., Zimmet, P. Z., Welborn, T. A., Jolley, D., Magliano, D. J., Dunstan, D. W., Cameron, A. J., Dwyer, T., Taylor, H. R., Tonkin, A. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685628 · Cited by 719
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Grundy, S. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1568 · Cited by 551
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Relationship of Lipoproteins to Cardiovascular Events
Guyton, J. R., Slee, A. E., Anderson, T., Fleg, J. L., Goldberg, R. B., Kashyap, M. L., Marcovina, S. M., Nash, S. D., O'Brien, K. D., Weintraub, W. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.023 · Cited by 182 · cited 2×
“However, the cardiovascular benefits of niacin may be restricted to patients with elevated plasma triglyceride and HDL cholesterol.(14) In addition, there is compelling data to support the use of niacin in combination with statins to treat the atherogenic dyslipidemia.”
BackgroundResultSelf-citation
Cited by
Highlighting Diabetes Mellitus: The Epidemic Continues
Schmidt, A. M. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310221 · Cited by 292
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
“Kinetic studies have indicated that extended-release niacin decreases the production of apo(a) and apoB-100–containing lipoproteins (79), increases the production of apoA-I, enhances the clearance of TRL apoB100 and apoB-48 (80), and reduces the fractional catabolic rate of apoA-I (81).”
BackgroundThomas, T., Zhou, H., Karmally, W., Ramakrishnan, R., Holleran, S., Liu, Y., Jumes, P., Wagner, J. A., Hubbard, B., Previs, S. F., et al. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309549 · Cited by 96
Self-citationImpact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001696 · Cited by 93
Self-citation
Metadata
- Authors
- Ooi, E. M., Watts, G. F., Chan, D. C., Pang, J., Tenneti, V. S., Hamilton, S. J., McCormick, S. P., Marcovina, S. M., & Barrett, P. H. R.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2015-12
- Volume
- 35
- Issue
- 12
- Pages
- 2686-2693
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2150538035
- Cited by
- 54
- References
- 7
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100–Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1161/atvbaha.115.306136
- The paper
- Ooi, E. M., Watts, G. F., Chan, D. C., Pang, J., Tenneti, V. S., Hamilton, S. J., McCormick, S. P., Marcovina, S. M., & Barrett, P. H. R. (2015). Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100–Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.115.306136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.